Mapping the MHC Class I-Spliced Immunopeptidome of Cancer Cells.
| Autor: | Liepe J; Max Planck Institute for Biophysical Chemistry, Göttingen, Germany. michele.mishto@kcl.ac.uk jliepe@mpibpc.mpg.de., Sidney J; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California., Lorenz FKM; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Sette A; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California., Mishto M; Centre for Inflammation Biology and Cancer Immunology (CIBCI) and Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom. michele.mishto@kcl.ac.uk jliepe@mpibpc.mpg.de.; Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Biochemie, Berlin, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer immunology research [Cancer Immunol Res] 2019 Jan; Vol. 7 (1), pp. 62-76. Date of Electronic Publication: 2018 Nov 13. |
| DOI: | 10.1158/2326-6066.CIR-18-0424 |
| Abstrakt: | Anticancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines. The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer. (©2018 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|